Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 342

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 2
Chunk 342
---
 such action does not increase the number of shares of common stock issuable under the 2022 Omnibus Plan.

We
do not need to obtain participant (or other interested party) consent for any such action (a) that is permitted pursuant to the adjustment
provisions of the 2022 Omnibus Plan; (b) to the extent we deem the action necessary to comply with any applicable law or the listing
requirements of any principal securities exchange or market on which our common stock is then traded; (c) to the extent we deem the action
is necessary to preserve favorable accounting or tax treatment of any award for us; or (d) to the extent we determine that such action
does not materially and adversely affect the value of an award or that such action is in the best interest of the affected participant
or any other person as may then have an interest in the award.

The
Administrator can cause a participant to forfeit any award, and require the participant to disgorge any gains attributable to the award,
if the participant engages in any action constituting, as determined by the Administrator in its discretion, cause for termination, or
a breach of a material company policy, any award agreement or any other agreement between the participant and us or one of our affiliates
concerning noncompetition, nonsolicitation, confidentiality, trade secrets, intellectual property, nondisparagement or similar obligations.

Any
awards granted under the 2022 Omnibus Plan, and any shares of common stock issued or cash paid under an award, will be subject to recoupment
our Compensation Recovery Policy (as described below), or any recoupment or similar requirement otherwise made applicable by law, regulation
or listing standards to us, or that may be provided for in any cash or equity award granted by us.

79

Compensation
of Directors

The
following table sets forth all compensation paid to our Board members during the year ended December 31, 2024:

    Name 
    Fees
    Earned or Paid in Cash ($)  
    Stock
    Awards ($)  
    Option
    Awards ($) (1)  
    Non-Equity
    Incentive Plan Compensation ($)  
    Change
    in Pension Value and Nonqualified Deferred Compensation Earnings ($)  
    All
    Other Compensation ($)  
    Total
    ($) 
  
    Matthew
    Whalen 
     -  
         -  
     16,525